Immune cell therapy shows promise for Hard-to-Treat IgG4 disease
NCT ID NCT07148791
First seen Sep 30, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tests a new treatment called anti-BCMA-CD19 CAR-T cells for adults with IgG4-related disease that hasn't improved with standard therapies. Participants will have their immune cells collected, receive a short course of chemotherapy, and then get an infusion of the modified cells. The goal is to see if this therapy is safe and can reduce disease activity over 26 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.